City
Epaper

Britain to test Pfizer, AstraZeneca jabs combo in 2 doses

By IANS | Updated: February 4, 2021 19:34 IST

London, Feb 4 Britain on Thursday launched a new clinical study to determine the effects of using different Covid-19 ...

Open in App

London, Feb 4 Britain on Thursday launched a new clinical study to determine the effects of using different Covid-19 vaccines for the first and second dose, AstraZeneca's vaccine for one dose and Pfizer-BioNTech's vaccine for the other.

The study will also gather immunological evidence on different intervals between the first and second dose for a mixed-vaccine regimen against control groups when the same vaccine is used for both doses, the UK's Department of Health and Social Care said in a statement.

The 13-month study in which over 800 patients are expected to take part will monitor the impact of the different dosing regimens on patients' immune responses, which have the potential to be higher or lower than from the same dose regimen.

Initial findings are expected to be released in the summer and the results could help understand the vaccines could be safely roll out in a more flexible manner depending on their availability.

Britain said that should the study show promising results it may consider reviewing the vaccine current regimen approach if needed, but only if proven to be safe.

"This is a hugely important clinical trial that will provide us with more vital evidence on the safety of these vaccines when used in different ways," Nadhim Zahawi, the Minister for Covid-19 Vaccine Deployment in the UK, said in a statement.

"Nothing will be approved for use more widely than the study, or as part of our vaccine deployment programme, until researchers and the regulator are absolutely confident the approach is safe and effective."

A same-dose regimen is currently implemented for the national Covid-19 vaccination programme, and there are no current plans for this to change, the government said.

Anyone who has received either the Pfizer or AstraZeneca vaccination as part of the UK-wide delivery plan will not be affected by this study.

They will receive their second dose from the same source and over the same 12-week interval.

( With inputs from IANS )

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Tags: FebruaryLondonBritainAstrazenecaPremier of saAdministrative capitalAstrazeneca plc.
Open in App

Related Stories

MumbaiMumbai Crime: Fraudsters Use Fake ED, SEBI Letters to Dupe Retired London Auditor of ₹15 Lakh; Cyber Police Recover Entire Amount

PuneNilesh Ghaywal, Pune Gangster and Accused in Kothrud Firing Case, Flees to London

BusinessTata Motors Shares Fall After JLR Faces ₹20,000 Crore Cyberattack Erasing FY25 Profits

InternationalDonald Trump Says London Mayor Sadiq Khan Among 'Worst' in World, Claims He Blocked Him from Royal Banquet

EntertainmentAnoushka Shankar and Arijit Singh Team Up for a Special Performance in London, Sitarist Says ‘There’s more to come’

Health Realted Stories

HealthLeprosy now a 'notifiable disease' in Maharashtra

HealthPM Modi is really nice: Children after meeting at Chhattisgarh's Sri Sathya Sai Sanjeevani child heart hospital

HealthCommitted to health partnership with Global South, India sends ARV drugs to Fiji

HealthCampaigns like Swasth Nari, Sashakt Parivar Abhiyaan to empower, transform women’s lives: PM

HealthOver 86 lakh Ayushman Vay Vandana cards created for senior citizens above 70 years: Govt